Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trifarotene PROs in Moderate Acne
NCT03915860Phase 3Completed
- Sponsor
- Galderma
- Start
- Mar 2019
- Primary completion
- Dec 2019
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of CD5789 cream vehicle in acne vulgaris, sponsored by Galderma. Primary endpoints: Change From Baseline in Dermatology Life Quality Index Total Score at 24 weeks, Change From Baseline in Children's Dermatology Life Quality Index Score at 24 weeks and 5 more. Started Mar 2019; status: completed.
02
Drugs
CD5789 cream vehicle
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT03915860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03915860.